HRMY - Company ID 0001802665
The table below shows Harmony Biosciences Holdings, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $868.45M | $714.73M | $582.02M | $437.86M | $305.44M | $159.74M |
| Cost of revenue | $198.34M | $156.81M | $121.24M | $83.48M | $55.52M | $27.74M |
| Gross profit | $670.11M | $557.92M | $460.79M | $354.37M | $249.92M | $132.00M |
| R&D | $189.59M | $145.82M | $76.06M | $70.89M | $30.37M | $19.45M |
Harmony Biosciences Holdings, Inc. reported annual revenue of $868.45M for fiscal year 2025. That is up 21.5% from $714.73M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $6.00M (FY 2019) to $868.45M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $152.54M |
| $110.35M |
| $95.29M |
| $84.02M |
| $63.91M |
| $39.75M |
| Operating income | $208.47M | $190.83M | $192.03M | $120.19M | $87.53M | $16.99M |
| Income tax | $56.38M | $46.31M | $44.54M | -$76.78M | $2.83M | - |
| Net income | $158.69M | $145.49M | $128.85M | $181.47M | $34.60M | -$36.94M |
| EPS (diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | -$2.48 |